I am presently consulting in the areas of biologics product development, project management, biosimilars, and antibody drug conjugates. I also advise companies on their early research and clinical drug development pipelines.

Responsible for Process Sciences, Manufacturing, Quality, Supply Chain management focused on the launch of Trodelvy in third line triple negative breast cancer in the United States in April 2020.

As part of the Executive Management Committee I helped build Seattle Genetics from an early biotech start up to a commercial biopharmaecutical company with a cancer therapy on the market in the United States and Canada and a strong portfolio of oncology based antibody-drug conjugates in preclinical and clinical development. I was responsible for establishing process sciences and manufacturing at Seattle Genetics. Over the course of 11 years I recruited and trained ~150 scientists, engineers and quality specialists that were responsible for the process development and manufacturing of our clinical candidates. Established the clinical and commercial supply chain network for antibody and antibody drug conjugate. Oversaw the manufacture of clinical supply materials for 9 antibody and antibody drug conjugate programs over a span of 11 years. I played a key role in the process development, manufacture, validation, and approval of the Adcetris commercial manufacturing process.

Responsible for the development of biologics based therapies